Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report

• Autores principales: Chanhee Han (Autor), Stefania Bellone (Autor), Peter E. Schwartz (Autor), Serengulam V. Govindan (Autor), Robert M. Sharkey (Autor), David M. Goldenberg (Autor), Alessandro D. Santin (Autor)
• Formato: Libro
• Publicado: Elsevier, 2018-08-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Background: Uterine serous carcinoma (USC) is a biologically aggressive variant of uterine cancer. Effective treatment options for recurrent, chemotherapy-resistant USC are extremely limited. Case: We describe a 74-year-old woman with recurrent and widespread treatment-resistant disease, who experie...